High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents

Junyi Ma; Liang Guo; Steve J. Fiene; Blake D. Anson; James A. Thomson; Timothy J. Kamp; Kyle L. Kolaja; Bradley J. Swanson; Craig T. January

doi:10.1152/ajpheart.00694.2011

Table 1.

Summary of drug-induced effects on evoked APs

Drug/Time or Dose	Peak	MDP	APD₁₀	APD₅₀	APD₉₀	dV/dt_max
Control solution (n = 5)
6 min	101.7 ± 3.6	99.6 ± 1.2	102.2 ± 1.9	102.3 ± 3.2	103.8 ± 2.2	98.3 ± 6.3
9 min	103.7 ± 4.4	96.8 ± 1.4	98.7 ± 1.7	98.4 ± 4.0	101.3 ± 2.8	94.5 ± 10.1
12 min	108.9 ± 6.3	94.8 ± 1.0	94.2 ± 2.4	97.2 ± 3.8	102.0 ± 2.6	92.8 ± 7.3
15 min	107.8 ± 5.8	93.8 ± 1.3	94.4 ± 2.3	96.4 ± 4.1	102.2 ± 3.0	86.4 ± 6.6
TTX (n = 5)
1 μM	103.8 ± 3.0	100.3 ± 0.9	107.1 ± 2.5	103.1 ± 1.9	101.7 ± 2.0	76.7 ± 7.4
3 μM	100.0 ± 1.3	99.5 ± 0.8	105.7 ± 4.3	100.6 ± 2.5	98.8 ± 0.8	41.2 ± 11.2^*
10 μM	99.0 ± 2.7	97.6 ± 1.1	108.8 ± 6.6	98.2 ± 4.3	96.4 ± 3.7	16.7 ± 1.8^*
30 μM	99.1 ± 3.6	96.2 ± 2.1	112.4 ± 6.3	102.0 ± 3.4	100.2 ± 3.1	16.8 ± 2.0^*
E4031 (n = 5)
3 nM	99.0 ± 1.0	99.8 ± 0.6	94.8 ± 3.4	95.5 ± 1.8	98.7 ± 2.0	98.9 ± 4.4
10 nM	100.5 ± 1.2	98.3 ± 0.8	92.2 ± 2.8	100.5 ± 1.6	112.8 ± 2.8	98.2 ± 5.9
30 nM	99.3 ± 1.0	97.4 ± 1.2	90.1 ± 3.0	109.1 ± 3.7^*	140.3 ± 7.6^*	90.1 ± 7.6
100 nM	101.1 ± 1.4	94.2 ± 2.6	83.0 ± 10.2	113.4 ± 3.9^*	170.42 ± 13.6^*	69.4 ± 17.1
0.1% DMSO control solution (n = 5)
6 min	97.6 ± 2.1	99.6 ± 0.5	100.8 ± 2.9	97.5 ± 2.7	99.3 ± 2.5	92.9 ± 3.1
9 min	94.3 ± 3.9	100.4 ± 0.7	101.8 ± 5.4	97.0 ± 4.6	97.8 ± 3.7	91.8 ± 4.5
12 min	96.2 ± 2.9	100.3 ± 0.7	104.1 ± 8.2	96.5 ± 6.0	95.5 ± 2.1	93.1 ± 4.3
15 min	96.6 ± 5.0	102.4 ± 2.6	106.4 ± 12.6	100.3 ± 10.3	98.4 ± 5.3	93.3 ± 3.5
Nifedipine (n = 4)
3 nM	89.5 ± 4.9	99.5 ± 0.4	83.3 ± 7.1^*	84.6 ± 2.4^*	89.4 ± 1.0^*	83.9 ± 14.5
10 nM	82.2 ± 9.0	98.7 ± 0.8	65.0 ± 12.3^*	70.3 ± 6.1^*	78.4 ± 4.4^*	91.3 ± 4.4
30 nM	87.2 ± 6.9	97.3 ± 1.8	60.9 ± 7.6^*	65.7 ± 3.0^*	74.0 ± 2.3^*	84.8 ± 11.2
100 nM	73.6 ± 12.2	96.6 ± 2.0	31.7 ± 11.1^*	45.4 ± 4.5^*	58.2 ± 5.4^*	87.7 ± 8.6
3R4S-Chromanol 239B (n = 5)
0.3 μM	106.5 ± 1.6	99.6 ± 0.8	99.8 ± 1.0	94.6 ± 1.2	95.7 ± 1.3	90.6 ± 4.9
1 μM	103.3 ± 3.7	96.8 ± 1.8	98.8 ± 1.8	92.7 ± 2.9	94.5 ± 2.7	86.9 ± 7.0
3 μM	102.7 ± 3.6	96.3 ± 1.6	98.8 ± 3.3	90.9 ± 4.3	92.8 ± 4.0	79.8 ± 8.7
10 μM	101.1 ± 4.9	96.0 ± 2.7	99.1 ± 3.7	91.1 ± 5.0	92.8 ± 4.3	72.4 ± 15.4

Date are means ± SE and are given as %control value recorded in extracellular solution (with or without DMSO) at the end of the initial 3-min long recording period. For control recordings, superfusion with extracellular solution (without or with DMSO) was continued for the entire experimental time period and was time-matched to drug application with the concentration increased at 3-min intervals. AP, action potential; TTX, tetrodotoxin; MDP, maximum diastolic potential; APD, AP duration at different levels of repolarization (APD measured at 10% increments of amplitude); dV/dt_max, maximal rate of depolarization.

^*P < 0.05 (shaded data).